Bio Age partners with Omar Labs to understand healthy longevity using samples and data from a prominent Northern European biobank.
The company will analyze longitudinal biological samples and clinical data to identify molecular pathways associated with healthy longevity, leading to the development of drug targets for aging diseases.
RICHMOND, Calif.--(BUSINESS WIRE)—Bio Age Labs, Inc. ("Bio Age", "the Company"), a biotechnology company developing therapies that target the molecular causes of aging to extend the healthy human lifespan. Announced today that it has entered into a partnership agreement with Age Labs AS ("Age Labs"), a diagnostics company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, Bio Age will perform multinomials analysis on samples and health records from the Nord Trøndelag Health Study (HUNT) biobank collected from more than 100,000 northern European volunteers over the age of 25 and apply machine learning. Will The resulting data methods reveal key molecular mechanisms of healthy human longevity? The agreement gives the company exclusive access to data generated by the partnership for the purpose of drug discovery.
"Biobanks in which samples from healthy people have been collected after decades of follow-up are extraordinarily rare," said Kristin Fortunes, Ph.D, Chief Executive Officer (CEO) and co-founder of Bio Edge. Said and may provide invaluable insights into the molecular basis of healthy longevity. Bio Age's AI-powered discovery platform, built on the analysis of human longevity data, of age-related diseases. Has already received multiple clinical-stage assets for treatment. This large and exclusive access to data generated from important biobanks will dramatically accelerate our ability to discover and target new aging mechanisms with our diverse and growing portfolio of drugs.
The HUNT biobank contains biological material, including blood samples suitable for proteomics and metabolomics analyzes, collected longitudinally since 1995. Biobanks are linked to data banks.
Includes health survey data, medical records, and mortality outcomes for all participants.
"High-quality longitudinal human data are ideal for investigating the biology of aging and discovering new antiaging targets," said Eric Morgan, MD, chief operations officer (COO) and co-founder of Bio Age. " Therefore, we are pleased to have the opportunity to analyze material from a biobank that has collected samples longitudinally from this population-based group of individuals over more than a quarter of a century. Importantly, the data bank containing each participant's medical records enables us to link our biological measurements to health outcomes, and thereby determine which pathways are most strongly associated with healthy longevity. Are associated with are
Bio Age's ML/AI-powered discovery platform deeply analyzes omits data from biological samples from longitudinal cohorts to reveal proteins and metabolites associated with healthy longevity or age-related pathology, and then age-related Identifies drug targets in key longevity pathways with therapeutic intent. disease. Edge Labs uses EPIPHANY, its machine learning-based biomarker discovery platform to develop biomarkers for early disease detection and predict drug response, focusing on aging and immunology.
Bio Age will use data generated through the partnership to identify, develop and commercialize drug targets for diseases of aging, while Age Labs will discover, develop and develop biomarkers for applications in diagnostics and clinical trials. Will prepare. Will make it commercial.
"Age Labs has developed an innovative method to derive actionable biomarkers of healthy aging and specifically to identify health risks before the onset of diagnostic disease," said Morgan. "We are excited to collaborate with Edge Labs on a project that will provide new insights into healthy longevity and bring substantial benefits to both companies."
Current agreements give Bio Age access to other biobanks in several distinct geographic regions with up to 45 years of follow-up after collecting blood samples from thousands of subjects. Biobank content is linked to health data including age, disease status, and functional and cognitive outcomes.
Bio Age is actively seeking to expand the company's human aging cohort data through additional biobank partnerships, with many currently under due diligence.
About Bio Age Labs, Inc.
Bio Age is a clinical-stage biotechnology company developing a pipeline of therapeutics to promote healthy aging by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records to map key molecular pathways influencing healthy human aging. By targeting aging mechanisms with a large and mechanistically diverse portfolio of drugs, Bio Age is opening up opportunities to treat or prevent age-related disease in entirely new ways. Bio Age currently has several clinical-stage programs in its growing portfolio targeting muscle, immunity, and brain aging. To date, Bio Age has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. Bio Age currently has three clinical-stage programs in its growing portfolio, for additional information about Bio Age.
You must be logged in to post a comment.